Skip to main content
The George Institute for Global Health
  • About us

    About us

    We are on a mission to improve global health. Through rigorous, high-quality research, we’re striving to achieve meaningful and lasting change on a local and global scale. 
    Discover who we are
    • Governance
      • Board of directors
      • Executive leadership team
      • Policies
      • Annual reports and financial statements
    • Our people
      • People at The George Institute
      • Emerging thought leaders
      • Distinguished fellows
    • Affiliates and partners
    • Innovation
    • Careers
    Medical research careers
    We are hiring!

    Careers

    At The George Institute, your work will help find solutions to some of the world’s greatest health challenges.  We are not just a workplace - we are a community united by a shared mission.
    Work with us
  • Our research

    Our research

    Our research finds solutions to some of the world’s biggest health challenges in critical areas including women’s health, planetary health, and food policy. Within each program, individual projects target specific challenges, providing local solutions to improve global outcomes.   
    Learn more about our research
    • Areas of our research
    • Our research projects
    • Clinical and community trials

    Our Research Mega Menu Cards Container

  • Our impact

    Our impact

    Our high quality, rigorous research makes a real difference to people's health, particularly those facing the most barriers.
    Find out more about the impact of our work
    • Stories of our impact
    • Policy statements and recommendations
    • Impact Report

    Impact Mega Menu Cards Container

  • News & media

    News and media

    Stay up to date with the latest breakthroughs, stories, and developments in global health research from The George Institute. Access articles, videos, and updates that spotlight our work across the world.
    Explore the latest news and insights
    • News
    • Events
    • Videos
    • Podcasts

    News and Media Mega Menu Cards Container

  • Support us

    Support us

    Help us make a lasting impact. By supporting our independent research, you fuel life-saving innovations that improve health outcomes for millions around the globe.
    See how you can support global health innovation
    • Donate
    • Ways to give
    • Your impact
    • Get involved

    Support us Mega Menu Cards Container

    Face of a woman looking ahead

    Be a part of our mission for healthier and longer lives

    Our research relies on the generous support of people like you. Show your support for breakthrough medical research today.
    Donate now
Donate

Filters

Filter by date

Clinical and community trials

About this study Intracerebral haemorrhage (ICH), bleeding into the brain, is the most serious and least treatable form of stroke, accounting for at least 10% of the 20 million new strokes that occur in the world each year. Patients fortunate enough to survive an ICH are at very high risk of another ICH as well as heart attacks and other serious heart-related events. Whilst there is strong evidence that these risks can be reduced by good control of blood pressure (BP), many patients do not receive any BP lowering treatment or that this treatment is inadequate. TRIDENT aims to determine the benefits of using three different BP medications (each at half the normal dose) in a single pill on preventing another stroke. This capsule with the three medications, is called the Triple Pill. The study is hoping to enrol and treat 1500 people. Recruitment criteria Inclusion criteria Adults with a history of ICH stroke Average resting BP in the 130-160 mmHg range

Clinical and community trials

About this study People with advanced kidney disease or those receiving dialysis often have other diseases related to the heart, brain and blood vessels, known as vascular disease (for example, heart attack, stroke and poor blood circulation). However, few treatments have been proven to prevent these conditions in people with advanced kidney disease. Blood thinners (medicines that prevent blood clots) are frequently used and proven to help other groups of people who are at high risk of vascular disease. There is little understanding of whether blood thinners provide similar benefits in people with advanced kidney disease. The aim of the TRACK study is to find out whether a low dose of blood thinning medicine can reduce heart and vascular disease better than placebo (a look alike tablet that contains no active medication) in people with advanced kidney disease. Recruitment criteria Inclusion: Age ≥18 years, Advanced kidney disease (kidney failure on dialysis, or

Global Surgery and Trauma Research

An estimated 11–32% of the global disease burden is due to surgically correctable illnesses. Lancet Commission on Global Surgery estimated that 5 billion people do not have adequate access to safe affordable surgical care when needed. Contrary to belief, investing in surgical services in low- and middle-income countries (LMICs) is affordable, saves lives, and promotes economic growth. Global Surgery is defined as an area of study, research, practice, and advocacy that seeks to improve health outcomes and achieve health equity for all people who need surgical and anaesthesia care, with a special emphasis on underserved populations and populations in crisis. Among these surgically treatable diseases, trauma causes over four million deaths annually, predominantly in LMICs and is an important aspect of Global surgery. Cancer, similarly, is the second most lethal noncommunicable disease after cardiovascular disease and accounted for about 9.9 million deaths, globally in 2020. Around 9% of all cancer death

The CEDAW Index

The United Nations (UN) treaty body system is a powerful mechanism for promoting human rights. The UN influences government action through monitoring, programs, and country-specific recommendations. In the context of women’s rights, the Committee on the Elimination of All Forms of Discrimination Against Women (CEDAW) influences government action by periodically reviewing 189 countries every four years. Governments report on their progress ahead of each review, and civil society organisations offer grassroots perspectives to the Committee in the form of ‘shadow reports’ which validate or challenge government narratives. The problem A significant challenge limiting the potential of the UN treaty body system is that the CEDAW Committee lacks clarity on the implementation of its recommendations, and their overall effectiveness in achieving health and social outcomes. Despite its 40-year history, CEDAW lacks a systematic monitoring tool to track implementation. Government

Join Us: Strengthening Australia’s research capability

Background Australia is a world leader in health and medical research, however an ongoing research barrier is the slow recruitment of research participants across the country. Increasing community involvement in medical research is a key goal for the government’s “National One Stop Shop” for clinical trials. Research registers are a proven way of connecting patients and researchers, but these registers typically address specific diseases, focus on people attending metropolitan centres of excellence, and can be difficult for patients to navigate. Disease-agnostic research registers offer participants of all types a single point of access to research. Aims Join Us is a not-for-profit, disease-agnostic health research register dedicated to connecting everyday Australians with meaningful research opportunities. Join Us aims to achieve better health and wellbeing for the Australian community by removing a major barrier to the recruitment of participant

Point Prevalence Program

The Point Prevalence Program (PPP) is a collaborative project between Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) and the Critical Care Division of The George Institute. Aim As a coordinated and validated project , the Point Prevalence Program provides  infrastructure to conduct several multi-centre observational studies simultaneously on specified study days each year. The impetus for the PPP is to improve the efficiency of the collection of observational data that helps design clinical trial protocols for future ANZICS CTG studies. A further use of the PPP is that it can help with generating data to understand how research findings are translated into clinical practice. Significance The program facilitates collaborations amongst members of the CTG with an average of 44 ICUs participating each study day from a range of tertiary, metropolitan, regional-rural and private hospitals with an average recruitment per study day of more than 550 participants.

Intensive Insulin Therapy Trialists' Collaboration (IIT-TC)

Hyperglycaemia is a common finding in patients who are acutely ill even in the absence of a prior diagnosis of diabetes mellitus. In acutely ill patients, hyperglycaemia is associated with a worse outcome. As hyperglycaemia is consistently associated with increased morbidity and mortality, critical care researchers have conducted a number of trials to investigate whether tighter control of blood glucose in critically ill patients is beneficial. To date there have been over 30 randomised controlled trials of tight glucose control in critical care settings. However, many studies have reported non-significant results; in part this is because many of the trials were small and when considered alone had insufficient statistical power to examine the effects of tight glucose control on mortality. Aims The aim of this collaborative research project is to combine the individual patient data from all randomized controlled trials of tight glucose control in critically ill adults around the world to conduct

Changes in clinical guidelines for the management of chronic back pain

Policy & Practice Report

Improving the management of stroke

Policy & Practice Report

Australian Government Preventative Health Taskforce

Policy & Practice Report

Developing renal service plans

Policy & Practice Report

Assessment of absolute cardiovascular disease risk

Policy & Practice Report

Pagination

  • Previous page
  • Page 121
  • Page 122
  • Page 123
  • Page 124
  • Page 125
  • Next page
globe illustration on desktop globe illustration on mobile
The George Institute for Global Health

    Quick links

    • About us
    • Our research
    • Our impact
    • News & media
    • Contact us

    Acknowledgement of country

    The George Institute acknowledges First Peoples and the Traditional Custodians of the many lands upon which we live and work. We pay our respects to Elders past and present, and thank them for ongoing custodianship of waters, lands and skies.

    Our Partners

    The George Institute for Global Health is proud to work in partnership with UNSW Sydney, Imperial College London and the Manipal Academy of Higher Education, India.

    Registered charity logo
    The George Institute for Global Health is a registered charity. ABN 90 085 953 331

    Stay connected

    Enter your details to subscribe to our newsletter.




    By submitting this form, you are agreeing to our Privacy Policy.


    reCAPTCHA helps prevent automated form spam.
    The submit button will be disabled until you complete the CAPTCHA.


    Disclaimer and policy menu

    • Disclaimer
    • Privacy policy
    • Data sharing policy
    • Whistleblower policy
    • Modern slavery statement
    • Working with children and adolescents' policy
    • Research code of conduct policy
    • PHS awards financial COI policy
    • Sitemap
    Affiliated with UNSW Sydney. In partnership with Imperial College London and Manipal Academy of Higher Education, India.

    Copyright © 2025 The George Institute for Global Health.

    Website by Marameo Design

    Cookie Policy | Privacy Policy